Valeant Pharma adds hedge fund executive, 2 others to board

Embattled drug company Valeant Pharmaceuticals has added three directors to its board, including an executive from activist investor Bill Ackman's hedge fund Pershing Square Capital Management.

Valeant Pharmaceuticals International Inc. is facing a Securities and Exchange Commission investigation and, separately, scrutiny from Congress over its drug pricing.

The company also has said it would delay filing its 2015 annual report with regulators while it sorts out its former relationship with the mail-order pharmacy Philidor, which has raised questions about the accuracy of Valeant's financial reporting.